OCEANSIX-FUTURE-PATHS-LT
15.2.2024 15:22:35 CET | Business Wire | Press release
oceansix Files Provisional Patent for Groundbreaking Packaging System
oceansix Future Paths Ltd. ("the Company" or "oceansix") is a publicly-traded Company on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0). oceansix is a technology and manufacturing company on an environmental mission, using plastic waste to create innovative products and build transformative businesses. The company is headquartered in Israel and operates a research and development centre and a production facility in Valencia, Spain.
oceansix Announces the Filing of a Provisional Patent Application for an Innovative Package System
With a continuous commitment to executing its business plan, oceansix marks a significant milestone in its journey towards revolutionising e-commerce packaging. Filed earlier this year, this invention is poised to set new standards in packaging efficiency and reusable systems.
Innovative Design for Sustainable Impact
The package, conceptualised by inventor Gat Ramon, features a unique design that addresses the pressing environmental concerns of traditional single-use packaging. It also solves the critical challenges companies face in ensuring the protection of their items during transit without adding excessive weight or bulk, thereby optimising shipping efficiency.
The packaging is also engineered to adapt to various product sizes, eliminating the need for excess cushioning materials and significantly reducing waste. With its ecological nature, it was designed to be manufactured from recycled materials and to be reused for up to 100 cycles; therefore, it fully aligns with oceansix's mission to foster sustainable practices across industries, particularly businesses where packaging and e-commerce are at their highest peak.
Addressing E-Commerce Challenges
oceansix's package is specifically designed to mitigate the environmental impact of e-commerce, targeting the waste generated by cardboard and plastic materials. The project aims to reduce CO2 emissions and enhance reverse logistics efficiency and cost-effectiveness, offering a scalable and automated-compatible solution that incorporates future features like real-time location tracking and unique identification with smart locking.
oceansix Joins TheCircularLab's goCircular Radar for Circular Economy Excellence
oceansix is honoured to announce its inclusion in the goCircular Radar by TheCircularLab, Europe's pioneering circular economy innovation centre. This distinction places oceansix on the map of leading startups in Europe's circular economy sector, highlighting the reusable packaging project's potential and opening avenues for collaboration.
oceansix Enhances Strategy with Expert Collaboration and New Incentive Options
In addition to our recent announcement about the packaging system, oceansix has granted 300,000 options to a consultant, with a strike price of CAD 0.29, valid for five years. This initiative is a key component of our broader strategy to collaborate with experts whose insights and expertise are vital in propelling our mission forward.
Join oceansix
oceansix invites stakeholders, partners, and the global community to join in its vision of creating impactful and sustainable solutions.
For more information about oceansix and its pioneering projects, please visit oceansix.com and connect with us on LinkedIn.
About oceansix
oceansix Future Paths Ltd. is a leader in developing radical, sustainable solutions and transforming waste into innovative products. Driven by a circular model and a vision to tackle some of Earth's most pressing challenges, oceansix combines advanced technology with sustainable practices to create meaningful solutions and successful global businesses.
Disclaimer
This press release may contain forward-looking statements based on current expectations and assumptions, subject to risks and uncertainties. Actual results may differ materially from those anticipated in these statements. oceansix assumes no obligation to update or revise any forward-looking information.
Approval & Accuracy
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215233336/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom